8-K - LIXT - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 23, 2023

LIXTE

BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

delaware	001-39717	20-2903526
(State<br> or other jurisdiction<br><br> <br>of<br> incorporation)	(Commission<br><br> <br>File<br> Number)	(I.R.S.<br> Employer<br><br> <br>Identification<br> Number)

680 East Colorado Boulevard, Suite 180

Pasadena California 91101

(Address of principal executive offices)

(631) 830-7092

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of Each Class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
Common<br> Stock, par value $0.0001 per share	LIXT	The<br> NASDAQ Stock Market, LLC
Warrants<br> to Purchase Common Stock, par value $0.0001 per share	LIXTW	The<br> NASDAQ Stock Market, LLC
Item 8.01.	Other Events.
---	---

On June 23, 2023, the Company issued a press release announcing that it has received confirmation from The Nasdaq Stock Market, LLC that it has regained compliance with the Nasdaq minimum bid price requirement.

Item 9.01.	Financial Statements and Exhibits.

(d) There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein by reference.

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> June 26, 2023	LIXTE<br> BIOTECHNOLOGY HOLDINGS, INC.
	By:	/s/ JOHN S. KOVACH
		John<br> S. Kovach, Chief Executive Officer

| 3 |

| --- |

INDEX

TO EXHIBITS

Exhibit No.	Description
99.1	Press Release announcing that the Company has received confirmation from The Nasdaq Stock Market, LLC that it has regained compliance with the Nasdaq minimum bid price requirement.
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

| 4 |

| --- |

Exhibit99.1

LIXTEBiotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

PASADENA, CA, June 23, 2023 — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.

On June 24, 2022, Nasdaq notified LIXTE that its common stock failed to maintain a minimum bid price of $1.00 per share over the previous 30 consecutive trading days as required by the Listing Rules of Nasdaq. In order to address this issue, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock on Friday, June 2, 2023, as a result of which the Company’s common stock commenced trading on a post-split basis beginning on Monday, June 5, 2023.

AboutLIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has achieved a breakthrough demonstrating that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE’s new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept clinical trials are in progress.

Formore information about LIXTE, contact:

info@lixte.com

General Phone: (631) 830-7092; Investor Phone: (888) 289-5533

PondelWilkinson Inc. Investor Relations

pwinvestor@pondel.com

Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962